Hepatitis B vaccine coverage among infants born to women without prenatal screening for hepatitis B virus infection: Effects of the Joint Statement on Thimerosal in Vaccines

Pediatric Infectious Disease Journal

Volumn 23, Issue 4, 2004, Pages 313-318

  Thomas, Ann R ^a   Fiore, Anthony E ^b   Corwith, Holly L ^a   Cieslak, Paul R ^a   Margolis, Harold S ^b  

^a Office of Disease Prevention and Epidemiology   (United States)

^b NATL CENTER FOR INFECTIOUS DISEASES   (United States)

Author keywords

Hepatitis B (prevention and control); Hepatitis B vaccine; Immunization programs; Thimerosal

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; METHYLMERCURY; THIOMERSAL;

ADULT; ARTICLE; BIRTH CERTIFICATE; ENVIRONMENTAL PROTECTION; FEMALE; HEPATITIS B; HIGH RISK POPULATION; HOSPITAL DISCHARGE; HUMAN; IMMUNIZATION; IMMUNOPROPHYLAXIS; INFANT; INFECTION CONTROL; INFECTION PREVENTION; MAJOR CLINICAL STUDY; MALE; PRENATAL CARE; PRENATAL SCREENING; PRIORITY JOURNAL; SCREENING TEST; TREATMENT FAILURE; VIRUS CARRIER; VIRUS INFECTION;

COHORT STUDIES; CONFIDENCE INTERVALS; CONSUMER PRODUCT SAFETY; FEMALE; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; HUMANS; IMMUNITY; IMMUNIZATION SCHEDULE; INFANT, NEWBORN; MALE; MASS SCREENING; OREGON; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PRENATAL CARE; PRESERVATIVES, PHARMACEUTICAL; PROBABILITY; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; THIMEROSAL; VACCINATION;

EID: 1942516440     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006454-200404000-00007     Document Type: Article

References (20)

1. 21 USC 397 Section 413.
2. Ball LK, Ball R, Pratt RD. An assessment of thimerosal use in childhood vaccines. Pediatrics 2001;107:1147-54.
3. American Academy of Pediatrics, Committee on Infectious Diseases and Committee on Environmental Health. Thimerosal in vaccines: an interim report to clinicians. Pediatrics 1999;104:570-4.
4. Centers for Disease Control and Prevention. Notice to readers: thimerosal in vaccines: a joint statement of the American Academy of Pediatrics and the Public Health Service. MMWR 1999;48:563-5.
5. Centers for Disease Control and Prevention. Notice to readers: availability of hepatitis B vaccine that does not contain thimerosal as a preservative. MMWR 1999;48:780-2.
6. Clark SJ, Cabana MD, Malik T, Yusuf H, Freed GL. Hepatitis B vaccination practices in hospital newborn nurseries before and after changes in vaccination recommendations. Arch Pediatr Adolesc Med 2001;155:915-20.
7. Hurie MB, Saari TN, Davis JP. Impact of the joint statement by the American Academy of Pediatrics/US Public Health Service on thimerosal in vaccines on hospital infant hepatitis B vaccination practices. Pediatrics 2001;107:755-8.
8. Centers for Disease Control and Prevention. Impact of the 1999 AAP/USPHS joint statement of thimerosal in vaccines on infant hepatitis B vaccination practices. MMWR 2001;50: 94-7.
9. Brayden RM, Pearson KA, Jones JS, Renfrew BL, Berman S. Effect of thimerosal recommendations on hospitals' neonatal hepatitis B vaccination policies. J Pediatr 2001;138:752-5.
10. Oram RJ, Daum RS, Seal JB, Lauderdale DS. Impact of recommendations to suspend the birth dose of hepatitis B virus vaccine. JAMA 2001;285:1874-9.
11. Biroscak BJ, Fiore TF, Fasano N, Fineis P, Collins MP, Stoltman G. Impact of the thimerosal controversy on hepatitis B vaccine coverage of infants born to women of unknown hepatitis B surface antigen status in Michigan. Pediatrics 2003;111:e645-9.
12. Schrag S, Arnold K, Mohle-Boetani J, et al. Prenatal screening for infectious diseases and opportunities for prevention, United States, 1998-1999. Obstet Gynecol 2003;102:753-60.
13. Silverman NS, Darby MJ, Ronkin SL, Wapner RJ. Hepatitis B prevalence in an unregistered prenatal population: implications for neonatal therapy. JAMA 1991;266:2852-5.
14. Barr D, Hershow R, Furner S, Handler A, Levy P. Assessing prenatal hepatitis B screening with an inexpensive study design adaptable to other jurisdictions. Am J Public Health 1999;89:19-24.
15. Centers for Disease Control and Prevention. Hepatitis B virus: a comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination. MMWR 1991;40:1-19.
16. Yusuf HR, Mahoney FJ, Shapiro CN, Mast EE, Polish L. Hospital-based evaluation of programs to prevent perinatal hepatitis B virus transmission. Arch Pediatr Adolesc Med 1996;150:593-7.
17. Clarkson TW, Magos L, Myers GJ. Current concepts: the toxicology of mercury-current exposures and clinical manifestations. N Engl J Med 2003;349:1731-7.
18. Pichichero ME, Cernichiari E, Lopricato J, Treanor J. Mercury concentrations and metabolism in infants receiving vaccines containing thimerosal: a descriptive study. Lancet 2002;360:1737-41.
19. Stratton K, Gable A, McCormick MC, eds. Immunization safety review: thimerosal-containing vaccines and neurodevelopmental disorders. Washington, DC: National Academy Press, 2001.
20. American Academy of Pediatrics, Committee on Infectious Diseases. Recommended childhood immunization schedule: United States, January-December 2002. Pediatrics 2002; 109:162-4.